LIVE ONLINE Conference Programme

default

Loading

Antimicrobial Resistance - Part 1

04 Nov 2021
Antimicrobial Resistance

(Timings are in Greenwich Mean Time - add session to your diary using link below)

Treating Acute Exacerbation of COPD with Chinese Herbal Medicine to aid Antibiotic Use Reduction

Introduction: Antimicrobial resistance is rising and linked to prescribing in primary care. Acute exacerbations of COPD (AECOPD) account for >2 million antibiotic prescriptions annually in the UK. However, many exacerbations are triggered by non-bacterial causes for which antibiotics have no benefit.  Preliminary research shows that Shufeng Jiedu (SFJD), a Chinese Herbal Medicine used in China to treat respiratory infections, can reduce risk of relapse and duration of hospitalisation for patients with AECOPD when combined with usual care. The authors hypothesise that adding SFJD to usual care in primary care may aid recovery and reduce the number of antibiotic prescriptions for AECOPD.  EXCALIBUR is a Phase III randomised controlled feasibility trial with nested qualitative substudy, investigating the feasibility of conducting a full trial of SFJD in addition to best current practice for AECOPD in UK primary care.

Co-Authors:

Dr Merlin Willcox - Academic Clinical Lecturer - University of Southampton
Prof Michael Moore - Professor - University of Southampton
Dr Xiao-Yang (Mio) Hu - NIHR Research Fellow - University of Southampton
Dr Beth Stuart - Associate Professor - University of Southampton
Professor Nick Francis - Professor of Primary Care Research - University of Southampton

 

Speakers
Thomas Oliver, Trial Manager, Southampton Clinical Trials Unit - UK

The joint congress for ESIM and ISCMR:

Organised in association with:

Gold Sponsors:


 

Silver Sponsors:


 

Supported by: